Testing the substrate-envelope hypothesis with designed pairs of compounds

ACS Chemical Biology

Volumn 8, Issue 11, 2013, Pages 2433-2441

  Shen, Yang ^a,c,f   Altman, Michael D ^b,g   Ali, Akbar ^d   Nalam, Madhavi N L ^c   Cao, Hong ^d   Rana, Tariq M ^d,e   Schiffer, Celia A ^d   Tidor, Bruce ^a,c  

^a Massachusetts Institute of Technology Cambridge   (United States)

^b MASSACHUSETTS INSTITUTE OF TECHNOLOGY   (United States)

^c Department of Electrical Engineering and Computer Science   (United States)

^d UNIVERSITY OF MASSACHUSETTS MEDICAL SCHOOL   (United States)

^e BURNHAM INSTITUTE   (United States)

^f TOYOTA TECHNOLOGICAL INSTITUTE AT CHICAGO   (United States)

^g Merck Research Laboratories Boston   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ABELSON KINASE; AMPRENAVIR; ATAZANAVIR; CHITINASE; DARUNAVIR; FOSAMPRENAVIR; HUMAN IMMUNODEFICIENCY VIRUS PROTEINASE; HUMAN IMMUNODEFICIENCY VIRUS PROTEINASE INHIBITOR; INDINAVIR; LOPINAVIR; NELFINAVIR; RITONAVIR; SAQUINAVIR; THYMIDYLATE SYNTHASE; TIPRANAVIR; VIRUS PROTEIN;

ANTIVIRAL ACTIVITY; ARTICLE; CRYSTAL STRUCTURE; DRUG DESIGN; DRUG RESISTANCE; DRUG SYNTHESIS; ENZYME INHIBITION; FLUORESCENCE RESONANCE ENERGY TRANSFER; MUTATION; PRIORITY JOURNAL; X RAY CRYSTALLOGRAPHY; ANTIVIRAL RESISTANCE; CHEMICAL STRUCTURE; CHEMISTRY; COMPUTER SIMULATION; DRUG EFFECTS; ENZYME SPECIFICITY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; IC50; METABOLISM;

COMPUTER SIMULATION; CRYSTALLOGRAPHY, X-RAY; DRUG RESISTANCE, VIRAL; HIV PROTEASE INHIBITORS; HIV-1; HUMANS; INHIBITORY CONCENTRATION 50; MODELS, MOLECULAR; MUTATION; SUBSTRATE SPECIFICITY; VIRAL STRUCTURAL PROTEINS;

EID: 84887949978     PISSN: 15548929     EISSN: 15548937     Source Type: Journal    
DOI: 10.1021/cb400468c     Document Type: Article

References (33)

1. Hayes, J. D. and Wolf, C. R. (1990) Molecular mechanisms of drug resistance Biochem. J. 272, 281-295
2. McManus, M. C. (1997) Mechanisms of bacterial resistance to antimicrobial agents Am. J. Health-Syst. Pharm. 54, 1420-1433
3. Walsh, C. (2000) Molecular mechanisms that confer antibacterial drug resistance Nature 406, 775-781
4. Krishna, R. and Mayer, L. D. (2000) Multidrug resistance (MDR) in cancer: Mechanisms, reversal using modulators of MDR and the role of MDR modulators in influencing the pharmacokinetics of anticancer drugs Eur. J. Pharm. Sci. 11, 265-283
5. Gottesman, M. M. (2002) Mechanisms of cancer drug resistance Annu. Rev. Med. 53, 615-627
6. Tenover, F. C. (2006) Mechanisms of antimicrobial resistance in bacteria Am. J. Med. 119, S3-S10
7. King, N. M., Prabu-Jeyabalan, M., Nalivaika, E. A., and Schiffer, C. A. (2004) Combating susceptibility to drug resistance: lessons from HIV-1 protease Chem. Biol. 11, 1333-1338
8. Wlodawer, A. and Erickson, J. W. (1993) Structure-based inhibitors of HIV-1 protease Annu. Rev. Biochem. 62, 543-585
9. Turner, S. R., Strohbach, J. W., Tommasi, R. A., Aristoff, P. A., Johnson, P. D., Skulnick, H. I., Dolak, L. A., Seest, E. P., Tomich, P. K., Bohanon, M. J., Horng, M.-M., Lynn, J. C., Chong, K.-T., Hinshaw, R. R., Watenpaugh, K. D., Janakiraman, M. N., and Thaisrivongs, S. (1998) Tipranavir (PNU-140690): A potent, orally bioavailable nonpeptidic HIV protease inhibitor of the 5,6-dihydro-4-hydroxy-2-pyrone sulfonamide class J. Med. Chem. 41, 3467-3476
10. Roberts, N. A., Martin, J. A., Kinchington, D., Broadhurst, A. V., Craig, J. C., Duncan, I. B., Galpin, S. A., Handa, B. K., Kay, J., Krohn, A., and Al, E. (1990) Rational design of peptide-based HIV proteinase inhibitors Science 248, 358-361
11. Kempf, D. J., Marsh, K. C., Denissen, J. F., McDonald, E., Vasavanonda, S., Flentge, C. A., Green, B. E., Fino, L., Park, C. H., and Kong, X. P. (1995) ABT-538 is a potent inhibitor of human immunodeficiency virus protease and has high oral bioavailability in humans Proc. Natl. Acad. Sci. U.S.A. 92, 2484-2488
12. Vacca, J. P., Dorsey, B. D., Schleif, W. A., Levin, R. B., McDaniel, S. L., Darke, P. L., Zugay, J., Quintero, J. C., Blahy, O. M., and Roth, E. (1994) L-735,524: an orally bioavailable human immunodeficiency virus type 1 protease inhibitor Proc. Natl. Acad. Sci. U.S.A. 91, 4096-4100
13. Kaldor, S. W., Kalish, V. J., Davies, J. F., Shetty, B. V., Fritz, J. E., Appelt, K., Burgess, J. A., Campanale, K. M., Chirgadze, N. Y., Clawson, D. K., Dressman, B. A., Hatch, S. D., Khalil, D. A., Kosa, M. B., Lubbehusen, P. P., Muesing, M. A., Patick, A. K., Reich, S. H., Su, K. S., and Tatlock, J. H. (1997) Viracept (nelfinavir mesylate, AG1343): A potent, orally bioavailable inhibitor of HIV-1 protease J. Med. Chem. 40, 3979-3985
14. Kim, E. E., Baker, C. T., Dwyer, M. D., Murcko, M. A., Rao, B. G., Tung, R. D., and Navia, M. A. (1995) Crystal structure of HIV-1 protease in complex with VX-478, a potent and orally bioavailable inhibitor of the enzyme J. Am. Chem. Soc. 117, 1181-1182
15. Baker, C., Chaturvedi, P. R., Hale, M. R., Bridson, G., Heiser, A., Furfine, E. S., Spaltenstein, A., and Tung, R. D. (1999) Discovery of VX-175/GW433908, a novel, water- soluble prodrug of amprenavir, in 39th Interscience Conference on Anti-microbial Agents and Chemotherapy, San Francisco, 26-29 Sep 1999, abstract 313.
16. Sham, H. L., Kempf, D. J., Molla, A., Marsh, K. C., Kumar, G. N., Chen, C.-M., Kati, W., Stewart, K., Lal, R., Hsu, A., Betebenner, D., Korneyeva, M., Vasavanonda, S., McDonald, E., Saldivar, A., Wideburg, N., Chen, X., Niu, P., Park, C., Jayanti, V., Grabowski, B., Granneman, G. R., Sun, E., Japour, A. J., Leonard, J. M., Plattner, J. J., and Norbeck, D. W. (1998) ABT-378, a highly potent inhibitor of the human immunodeficiency virus protease Antimicrob. Agents Chemother. 42, 3218-3224
17. Robinson, B. S., Riccardi, K. A., Gong, Y., Guo, Q., Stock, D. A., Blair, W. S., Terry, B. J., Deminie, C. A., Djang, F., Colonno, R. J., and Lin, P. (2000) BMS-232632, a highly potent human immunodeficiency virus protease inhibitor that can be used in combination with other available antiretroviral agents Antimicrob. Agents Chemother. 44, 2093-2099
18. Surleraux, D. L. N. G., Tahri, A., Verschueren, W. G., Pille, G. M. E., de Kock, H. A., Jonckers, T. H. M., Peeters, A., De Meyer, S., Azijn, H., Pauwels, R., de Bethune, M.-P., King, N. M., Prabu-Jeyabalan, M., Schiffer, C. A., and Wigerinck, P. B. T. P. (2005) Discovery and selection of TMC114, a next generation HIV-1 protease inhibitor J. Med. Chem. 48, 1813-1822
19. Prabu-Jeyabalan, M., Nalivaika, E., and Schiffer, C. A. (2002) Substrate shape determines specificity of recognition for HIV-1 protease: Analysis of crystal structures of six substrate complexes Structure 10, 369-381
20. Chellappan, S., Kairys, V., Fernandes, M. X., Schiffer, C., and Gilson, M. K. (2007) Evaluation of the substrate envelope hypothesis for inhibitors of HIV-1 protease Proteins Struct. Funct. Bioinf. 68, 561-567
21. Nalam, M. N. L., Ali, A., Altman, M. D., Reddy, G. S. K. K., Chellappan, S., Kairys, V., Ozen, A., Cao, H., Gilson, M. K., Tidor, B., Rana, T. M., and Schiffer, C. A. (2010) Evaluating the substrate-envelope hypothesis: structural analysis of novel HIV-1 protease inhibitors designed to be robust against drug resistance J. Virol. 84, 5368-5378
22. Kairys, V., Gilson, M. K., Lather, V., Schiffer, C. A., and Fernandes, M. X. (2009) Toward the design of mutation-resistant enzyme inhibitors: Further evaluation of the substrate envelope hypothesis Chem. Biol. Drug Des. 74, 234-245
23. Romano, K. P., Ali, A., Royer, W. E., and Schiffer, C. A. (2010) Drug resistance against HCV NS3/4A inhibitors is defined by the balance of substrate recognition versus inhibitor binding Proc. Natl. Acad. Sci. U.S.A. 107, 20986-20991
24. Romano, K. P., Laine, J. M., Deveau, L. M., Cao, H., Massi, F., and Schiffer, C. A. (2011) Molecular mechanisms of viral and host cell substrate recognition by hepatitis C virus NS3/4A protease J. Virol. 85, 6106-6116
25. Altman, M. D., Ali, A., Kumar Reddy, G. S. K., Nalam, M. N. L., Anjum, S. G., Cao, H., Chellappan, S., Kairys, V., Fernandes, M. X., Gilson, M. K., Schiffer, C. A., Rana, T. M., and Tidor, B. (2008) HIV-1 protease inhibitors from inverse design in the substrate envelope exhibit subnanomolar binding to drug-resistant variants J. Am. Chem. Soc. 130, 6099-6113
26. Parai, M. K., Huggins, D. J., Cao, H., Nalam, M. N. L., Ali, A., Schiffer, C. A., Tidor, B., and Rana, T. M. (2012) Design, synthesis, and biological and structural evaluations of novel HIV-1 protease inhibitors to combat drug resistance J. Med. Chem. 55, 6328-6341
27. Huggins, D. J., Sherman, W., and Tidor, B. (2012) Rational approaches to improving selectivity in drug design J. Med. Chem. 55, 1424-1444
28. Tie, Y., Kovalevsky, A. Y., Boross, P., Wang, Y.-F., Ghosh, A. K., Tozser, J., Harrison, R. W., and Weber, I. T. (2007) Atomic resolution crystal structures of HIV-1 protease and mutants V82A and I84V with saquinavir Proteins Struct. Funct. Bioinforma. 67, 232-242
29. Irwin, J. J. and Shoichet, B. K. (2005) ZINC-A free database of commercially available compounds for virtual screening J. Chem. Inf. Model. 45, 177-182
30. Ali, A., Kiran Kumar Reddy, G. S., Nalam, M. N. L., Anjum, S. G., Cao, H., Schiffer, C. A., and Rana, T. M. (2010) Structure-based design, synthesis and structure-activity relationship studies of HIV-1 protease inhibitors incorporating phenyloxazolidinones J. Med. Chem. 53, 7699-7708
31. Matayoshi, E. D., Wang, G. T., Krafft, G. A., and Erickson, J. (1990) Novel fluorogenic substrates for assaying retroviral proteases by resonance energy transfer Science 247, 954-958
32. Ali, A., Reddy, G. S. K. K., Cao, H., Anjum, S. G., Nalam, M. N. L., Schiffer, C. A., and Rana, T. M. (2006) Discovery of HIV-1 protease inhibitors with picomolar affinities incorporating N-aryl-oxazolidinone-5-carboxamides as novel P2 ligands J. Med. Chem. 49, 7342-7356
33. King, N. M., Melnick, L., Prabu-Jeyabalan, M., Nalivaika, E. A., Yang, S., Gao, Y., Nie, X., Zepp, C., Heefner, D. L., and Schiffer, C. A. (2002) Lack of synergy for inhibitors targeting a multi-drug-resistant HIV-1 protease Protein Sci. 11, 418-429